We are live on
!
Find out more
Arrowstreet Capital Portfolio holdings
AUM
$185B
1-Year Est. Return
39.58%
This Fund
S&P 500
This Quarter
Est. Return
+10.23%
1 Year Est. Return
+39.58%
3 Year Est. Return
+145.48%
5 Year Est. Return
+192.07%
10 Year Est. Return
+749.68%
AUM
$43B
AUM Growth
+$121M
(+0.28%)
Cap. Flow
-$3.21B
Cap. Flow
% of AUM
-7.47%
Top 10 Holdings %
Top 10 Hldgs %
18.86%
Holding
2,029
New
505
Increased
717
Reduced
446
Closed
331
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$285M |
| 2 |
Applied Materials
AMAT
|
+$234M |
| 3 |
Micron Technology
MU
|
+$185M |
| 4 |
Merck
MRK
|
+$161M |
| 5 |
NXP Semiconductors
NXPI
|
+$152M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$505M |
| 2 |
Bank of America
BAC
|
+$339M |
| 3 |
Nike
NKE
|
+$335M |
| 4 |
Union Pacific
UNP
|
+$329M |
| 5 |
Citigroup
C
|
+$277M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.49% |
| 2 | Financials | 16.82% |
| 3 | Consumer Discretionary | 16.55% |
| 4 | Healthcare | 14.39% |
| 5 | Industrials | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
Voyager Therapeutics
VYGR
$201M
| $682K | ﹤0.01% |
+48,900
| New | +$711K |
|
1427
Allot
ALLT
$383M
| $676K | ﹤0.01% |
79,295
-4,966
| -6% | -$40.7K |
|
1428
Integra LifeSciences
IART
$1.34B
| $676K | ﹤0.01% |
+11,600
| New | +$691K |
|
|
DLA
1429
DELISTED
Delta Apparel Inc.
DLA
| $676K | ﹤0.01% |
+21,731
| New | +$582K |
|
1430
Minerva Neurosciences
NERV
$199M
| $674K | ﹤0.01% |
+11,857
| New | +$523K |
|
1431
Paysign
PAYS
$705M
| $672K | ﹤0.01% |
66,250
+5,824
| +10% | +$61.2K |
|
|
RAVN
1432
DELISTED
Raven Industries Inc
RAVN
| $671K | ﹤0.01% |
+19,475
| New | +$664K |
|
|
CHK
1433
DELISTED
Chesapeake Energy Corporation
CHK
| $671K | ﹤0.01% |
+4,062
| New | +$816K |
|
1434
Orthofix Medical
OFIX
$419M
| $670K | ﹤0.01% |
+14,500
| New | +$682K |
|
1435
Methanex
MEOH
$4.12B
| $660K | ﹤0.01% |
17,100
-272,980
| -94% | -$10.2M |
|
|
CLGX
1436
DELISTED
Corelogic, Inc.
CLGX
| $656K | ﹤0.01% |
15,000
+9,100
| +154% | +$387K |
|
1437
Forrester Research
FORR
$224M
| $652K | ﹤0.01% |
15,636
-7,680
| -33% | -$286K |
|
|
MPX
1438
DELISTED
Marine Products Corp
MPX
| $651K | ﹤0.01% |
45,192
-3,200
| -7% | -$46.3K |
|
1439
IES Holdings
IESC
$15.2B
| $650K | ﹤0.01% |
25,318
-3,765
| -13% | -$81.5K |
|
|
IBTX
1440
DELISTED
Independent Bank Group, Inc.
IBTX
| $649K | ﹤0.01% |
+11,700
| New | +$650K |
|
1441
Nelnet
NNI
$4.7B
| $640K | ﹤0.01% |
10,988
-56,660
| -84% | -$3.47M |
|
1442
Orion Energy Systems
OESX
$80.6M
| $640K | ﹤0.01% |
19,108
+4,266
| +29% | +$128K |
|
|
MMAC
1443
DELISTED
MMA Capital Holdings, Inc. Common Stock
MMAC
| $634K | ﹤0.01% |
+19,950
| New | +$629K |
|
|
ATTO
1444
DELISTED
Atento S.A.
ATTO
| $630K | ﹤0.01% |
43,539
-10,984
| -20% | -$156K |
|
|
PDLI
1445
DELISTED
PDL BioPharma, Inc.
PDLI
| $630K | ﹤0.01% |
194,000
-204,950
| -51% | -$595K |
|
|
JMEI
1446
DELISTED
Jumei International Holding Limited American depositary shares, each representing ten Class A ordina
JMEI
| $625K | ﹤0.01% |
30,490
-8,654
| -22% | -$171K |
|
1447
Fate Therapeutics
FATE
$326M
| $624K | ﹤0.01% |
+31,900
| New | +$507K |
|
1448
i3 Verticals
IIIV
$342M
| $624K | ﹤0.01% |
22,101
-6,100
| -22% | -$144K |
|
1449
Myriad Genetics
MYGN
$312M
| $624K | ﹤0.01% |
+22,900
| New | +$630K |
|
1450
Tyson Foods
TSN
$20.4B
| $619K | ﹤0.01% |
6,800
+600
| +10% | +$51.6K |
|
Similar funds
VGA
Arrowstreet Capital's Q4 2019 Portfolio in Review
As of Q4 2019, Arrowstreet Capital held 2,029 positions worth $43B, up 0.28% from $42.9B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Arrowstreet Capital withdrew a net $3.21B in Q4 2019, closing 331 positions and reducing 446 holdings. Its most notable exit was Celgene Corp, an estimated $505M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 19% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Arrowstreet Capital opened a new position in Edwards Lifesciences worth $127M.
- Arrowstreet Capital's largest Q4 2019 buy was Edwards Lifesciences: 1,637,208 shares worth $127M.
- Arrowstreet Capital added most to Intel in Q4 2019, an estimated $285M increase.
- Arrowstreet Capital's biggest Q4 2019 reduction was Union Pacific, cutting an estimated $329M.
- Arrowstreet Capital fully exited Celgene Corp in Q4 2019, selling an estimated $505M.
- Arrowstreet Capital's ten largest holdings make up 19% of its $43B portfolio in Q4 2019.
- Arrowstreet Capital opened 505 new positions and closed 331 in Q4 2019.
- Arrowstreet Capital's portfolio value rose 0.28% quarter-over-quarter to $43B.
Based on Arrowstreet Capital's 13F filing for Q4 2019, filed 13 Feb 2020.